Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tricyclazole is a systemic fungicide primarily used for the control of rice blast disease caused by Pyricularia oryzae. It acts as a melanin biosynthesis inhibitor by specifically inhibiting melanization within the appressorium of the fungus. This inhibition prevents proper formation and rigidity of the appressorial wall required for fungal penetration into plant tissue. As a result, tricyclazole protects plants from infection but does not cure existing infections; its activity is protective rather than curative. The compound has no significant effect on spore germination but reduces sporulation and can influence pathogenicity in other fungi by damaging cell structures and reducing melanin production. There are also reports that tricyclazole may have adverse effects on mammalian reproductive systems in animal studies[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tricyclazole.